Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06393452 · ClinicalTrials.gov registry record · Phase 2
Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA
A Phase 2 study of Androgenetic Alopecia, sponsored by Pelage Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
- 8
- Study locations
NCT06393452: Completed Phase 2 study of Androgenetic Alopecia, sponsored by Pelage Pharmaceuticals.
NCT06393452 is a Phase 2 study of Androgenetic Alopecia that has completed, run by Pelage Pharmaceuticals. The registered enrollment target is 78 participants, below the 160-participant average among 16 other Androgenetic Alopecia trials with a reported enrollment target (51% lower). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06393452, a Phase 2 study of Androgenetic Alopecia, has completed, sponsored by Pelage Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
- 8
- Study locations
Study Summary
The study is a two part study, designed to validate safety results from the Phase 1 PP405-001 trial while also characterizing longer term safety and PK. Part 1 of the trial is the randomized controlled portion that will focus on safety and PK following 28 days of blinded treatment administration with either PP405 or vehicle control. Part 2 of the trial is an open-label extension that will validate the results of Part 1 with 3 months of treatment administration.
Primary Outcome
Collection of adverse events, treatment emergent adverse events and serious adverse events.
Conditions Studied
Interventions
- DRUG PP405 0.05% Topical Gel
- DRUG PP405 Topical Vehicle Gel
Study Locations (8)
California
- California Dermatology & Clinical Research Institute - Encinitas
- Clinical Trials Research Institute - Thousand Oaks
Texas
- DermResearch - Austin
- Stride Clinical Research LLC - Sugar Land
Indiana
- Dawes Fretzin Clinical Research Group, LLC - Indianapolis
Minnesota
- Minnesota Clinical Study Center - New Brighton
Utah
- Jordan Valley Dermatology Center - South Jordan
Virginia
- Virginia Clinical Research, Inc. - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2024-06-05 |
| Est. Completion | 2025-10-01 |
| Phase | Phase 2 |
What the finished NCT06393452 record still lists
NCT06393452 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 160-participant average among 16 other Androgenetic Alopecia trials with a reported enrollment target (51% lower).
The record links to 1 condition, with Androgenetic Alopecia appearing as the primary indexed condition, and to 2 interventions - of which PP405 0.05% Topical Gel is the first listed.
NCT06393452 lists 8 locations in 6 states (California, Texas, Indiana).
Frequently Asked Questions
What is clinical trial NCT06393452 about?
NCT06393452 is a clinical study titled "Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA". The study is a two part study, designed to validate safety results from the Phase 1 PP405-001 trial while also characterizing longer term safety and PK. Part 1 of the trial is the randomized controlled portion that will focus on safety and PK following 28 days of blinded treatment administration wit...
What is the current status of trial NCT06393452?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2024-06-05. Estimated completion is 2025-10-01.
What conditions does trial NCT06393452 study?
This clinical trial studies the following conditions: Androgenetic Alopecia.
What interventions are being tested in trial NCT06393452?
The interventions under investigation include: PP405 0.05% Topical Gel (DRUG), PP405 Topical Vehicle Gel (DRUG).
Who is sponsoring clinical trial NCT06393452?
This trial is sponsored by Pelage Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06393452 being conducted?
This trial has 8 study locations across California, Indiana, Minnesota, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Androgenetic Alopecia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06393452's enrollment target sits among peer trials
78 6th of 16 higher than 11 of 16 other Androgenetic Alopecia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Androgenetic Alopecia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Efficacy of VDPHL01 in Males and Females With AGA
ACTIVE NOT RECRUITING · Phase 2
-
Use of Botulinum Toxin in the Treatment of Androgenic Alopecia
ACTIVE NOT RECRUITING · Phase 2
-
Efficacy and Safety of VDPHL01 in Males With AGA
ACTIVE NOT RECRUITING · Phase 2
-
A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing
COMPLETED · Phase 2
-
A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004542)
COMPLETED · Phase 2
-
A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI